<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01236352</url>
  </required_header>
  <id_info>
    <org_study_id>CA215-001</org_study_id>
    <nct_id>NCT01236352</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose of BMS-911543</brief_title>
  <official_title>A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable
      in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to
      permit clinical testing at the Maximum Tolerated Dose or at a Clinically Active Dose, and to
      determine if BMS-911543 will demonstrate efficacy in symptomatic myelofibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endpoint Classification:

      Phase 1: Dose Ranging/Safety

      Phase 2: Safety/Efficacy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by medical review of adverse events and results of vital signs, Electrocardiograms (ECGs), physical examinations, and lab tests and evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0</measure>
    <time_frame>Approximately 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total number of subjects with the Investigator reported Complete Remission (CR), Partial remission (PR), or Clinical improvement (CI) divided by the total number of treated subjects</measure>
    <time_frame>Approximately 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacodynamics (PD) of BMS-911543</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>PD Biomarker endpoints will be determined by changes in (Janus kinase) JAK/signal transducers and activators of transcription (STATs) pathway activities, circulating CD34+ cells and plasma cytokine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-911543 and it's metabolite BMS-926796 (Met4)</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed (pre-dose) plasma concentration (Cmin) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (for single dose period only) (AUC(INF)) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the time of last quantifiable plasma concentration (for single dose period only) (AUC(0-T)) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The terminal-phase elimination half-life in plasma (T-HALF) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance (for parent compound only) (CLT/F) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution after first dosing based on the terminal phase (for parent compound only) (Vz/F) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index; ratio of AUC(TAU) on Day 15 of cycle 1 to AUC(TAU) after the first dose (AI) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of BMS-926796 AUC(INF) to BMS-911543 AUC(INF) after 1st dose and BMS-926796 AUC(TAU) to BMS-911543 AUC(TAU) on Day 15 of cycle 1 (AUCratio) of BMS-911543 and it's metabolite Met4</measure>
    <time_frame>23 timepoints approximately up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 1): BMS-911543 (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 2): BMS-911543 (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 3): BMS-911543 (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 4): BMS-911543 (40 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 5): BMS-911543 (80 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 6): BMS-911543 (120 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 7): BMS-911543 (160 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 8): BMS-911543 (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 9): BMS-911543 (240 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 (Cohort 10): BMS-911543 (320 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (Cohort 11): BMS-911543 (120 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (Cohort 12): BMS-911543 (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-911543</intervention_name>
    <arm_group_label>Phase 1 (Cohort 1): BMS-911543 (5 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 2): BMS-911543 (10 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 3): BMS-911543 (20 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 4): BMS-911543 (40 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 5): BMS-911543 (80 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 6): BMS-911543 (120 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 7): BMS-911543 (160 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 8): BMS-911543 (200 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 9): BMS-911543 (240 mg)</arm_group_label>
    <arm_group_label>Phase 1 (Cohort 10): BMS-911543 (320 mg)</arm_group_label>
    <arm_group_label>Phase 2 (Cohort 11): BMS-911543 (120 mg)</arm_group_label>
    <arm_group_label>Phase 2 (Cohort 12): BMS-911543 (200 mg)</arm_group_label>
    <other_name>JAK2 Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Men and Women at least 18 years old

          -  A diagnosis of symptomatic, primary or secondary Myelofibrosis (MF) [World Health
             Organization (WHO) 2008 criteria] with intermediate-1, intermediate-2 or high risk
             disease as assessed using the Dynamic International Prognostic Scoring System
             international prognostic scoring system

          -  Last therapeutic or diagnostic treatment at least 28 days prior

          -  Any toxicity from prior therapies must have resolved to Grade ≤1

          -  Adequate Liver and Kidney Function

          -  Serum amylase and lipase within normal institutional range

          -  Platelet count ≥50,000 cell mm³

          -  Absolute neutrophil count (ANC) ≥1,000 cells/mm3

          -  Hemoglobin ≥8.0 g/dL

        Exclusion Criteria:

          -  Primary central nervous system tumors

          -  Subjects with currently active malignancy (other than MF) or with a prior history of
             malignancy with the exception of: (i) adequately treated basal cell carcinoma of the
             skin, (ii) curatively treated in situ carcinoma of the cervix, (iii) other malignancy
             that has undergone potentially curative therapy with no evidence of disease recurrence
             ≥3 years

          -  Any condition requiring chronic use of moderate/high dose steroids except inhalation
             or oral steroids for mild pulmonary disease

          -  Splenic irradiation ≤3 months prior to treatment with study drug

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen or Human
             Immunodeficiency Virus-1 (HIV-1), or HIV-2 antibodies

          -  Abnormalities in serum electrolytes

          -  Significant cardiovascular disease

          -  Current or recent gastrointestinal disease

          -  Previous history of pancreatitis and/or significant risk factors for pancreatitis as
             judged by the treating physician

          -  Evidence of uncontrolled active infection or active graft vs. host disease

          -  Inability to tolerate oral medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai School Of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2010</study_first_submitted>
  <study_first_submitted_qc>November 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2010</study_first_posted>
  <disposition_first_submitted>March 22, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 23, 2017</disposition_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancer, Various, NOS</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

